Study shows minocycline has no benefit in slowing, preventing GA expansion in patients with dry AMD

News
Article

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

Physician administering AMD screening Image Credit: AdobeStock/RFBSIP

Image Credit: AdobeStock/RFBSIP

A recent study on minocycline showed that the drug has no benefit in preventing or slowing vision loss related to geographic atrophy (GA) expansion in people with dry age-related macular degeneration (AMD).1

The study, led by Tiarnan Keenan, MD, PhD, a Stadtman Tenure-Track Investigator at the NEI’s Division of Epidemiology and Clinical Applications, tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss. It was a multi-center, prospective, single-arm, phase II study that enrolled 37 patients at the NIH Clinical Center in Bethesda, Maryland, and at the Bristol Eye Hospital, United Kingdom.1

The trial had a 9-month run-in phase where researchers tracked each participant’s rate of GA expansion. Afterward, participants in the trial took twice-daily, oral, 100mg doses of minocycline for 2 years. After comparing each participant’s rate of GA expansion while taking minocycline to their baseline rate, they found there was no difference in GA expansion rate or vision loss with minocycline. Data showed the mean square root GA enlargement rate was 0.31 mm per year during the 9-month run-in phase and 0.28 mm per year during the 24-month treatment phase.2

Of the 37 patients (mean age of 74.3 [± 7.6 years]) enrolled , 36 initiated the treatment phase. Of those patients, 58% (21 patients) completed at least 33 months of treatment. Fifteen patients discontinued treatment; 8 by request, 6 for adverse events/illness and 1 death not related to treatment.2,3 Of the 129 treatment-emergent adverse events among 32 participants, 49 (38%) were related to minocycline (with no severe or ocular events), including elevated thyrotropin level (15 participants) and skin hyperpigmentation/discoloration (8 participants).

Previous studies have shown that minocycline can help reduce inflammation and microglial activity in the eye, including the retina, and has shown beneficial results for conditions such as diabetic retinopathy.

References:
  1. Inflammation-reducing drug shows no benefit for dry age-related macular degeneration in NIH trial. Press release; March 20, 2024. Accessed March 21, 2024. https://www.nih.gov/news-events/news-releases/inflammation-reducing-drug-shows-no-benefit-dry-age-related-macular-degeneration-nih-trial
  2. Keenan TDL, Bailey C, Abraham M, et al. Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration: A Nonrandomized Controlled Trial. JAMA Ophthalmol. Published online March 14, 2024. doi:10.1001/jamaophthalmol.2024.0118
  3. Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration. ClinicalTrials.gov. Updated February 1, 2024. Accessed March 21, 2024. https://clinicaltrials.gov/study/NCT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
© 2025 MJH Life Sciences

All rights reserved.